Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1980;10(Suppl 1):71S–80S. doi: 10.1111/j.1365-2125.1980.tb04909.x

Differences in psychic performance with guanfacine and clonidine in normotensive subjects

J Kugler, R Seus, R Krauskopf, H M Brecht, A Raschig
PMCID: PMC1430114  PMID: 6994783

Abstract

1 Doses of clonidine 0.15 mg or guanfacine 1.0 mg, respectively, and 2 h later additional doses of clonidine 0.3 mg or guanfacine 2.0 mg, respectively, were given to 24 healthy students.

2 Blood pressure was reduced by the same amount by both drugs.

3 Plasma noradrenaline concentrations decreased with both drugs, but the reduction was significantly greater following the administration of clonidine.

4 Mental activity in the EEG was less suppressed in the guanfacine group than in the clonidine group. The differences were statistically significant.

5 Self-estimations for well-being and mood showed only small changes due to guanfacine but significant changes due to clonidine.

6 The decrease of information processing and the increase in reaction time, measured by performance in different psychometric tests, were significantly more pronounced after clonidine treatment than guanfacine.

7 A dose-response relationship could only be observed in vigilosomnograms, in the tests of self-estimation related to well-being and mood and in the decrease in plasma noradrenaline in the clonidine group.

8 It was concluded that guanfacine had a lesser CNS depressant action than clonidine, when administered in equipotent hypotensive doses.

Full text

PDF
79S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton H., Rawlins M. D. Central nervous system depressant actions of clonidine and UK-14,304: partial dissociation of EEG and behavioural effects. Br J Clin Pharmacol. 1978 Feb;5(2):135–140. doi: 10.1111/j.1365-2125.1978.tb01614.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brecht H. M., Banthien F., Schoeppe W. Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension. Klin Wochenschr. 1976 Nov 15;54(22):1095–1105. doi: 10.1007/BF01469113. [DOI] [PubMed] [Google Scholar]
  3. Brunner H., Djawan S., Dorda W., Penner E., Grabner G. Ein neues Antihypertensivum der Imidazolinreihe: 5-Fluor-2-methyl-imidazolidinyliden-benzamin-monohydrochlorid (Flutonidin). Arzneimittelforschung. 1977;27(8):1599–1604. [PubMed] [Google Scholar]
  4. Davies D. S., Wing A. M., Reid J. L., Neill D. M., Tippett P., Dollery C. T. Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther. 1977 May;21(5):593–601. doi: 10.1002/cpt1977215593. [DOI] [PubMed] [Google Scholar]
  5. Dollery C. T., Davies D. S., Draffan G. H., Dargie H. J., Dean C. R., Reid J. L., Clare R. A., Murray S. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther. 1976 Jan;19(1):11–17. doi: 10.1002/cpt197619111. [DOI] [PubMed] [Google Scholar]
  6. Haeusler G. Cardiovascular regulation by central adrenergic mechanisms and its alteration by hypotensive drugs. Circ Res. 1975 Jun;36(6 Suppl 1):223–232. doi: 10.1161/01.res.36.6.223. [DOI] [PubMed] [Google Scholar]
  7. Haeusler G. Studies on the possible contribution of a peripheral presynaptic action of clonidine and dopamine to their vascular effects under in vivo conditions. Naunyn Schmiedebergs Arch Pharmacol. 1976 Dec;295(3):191–202. doi: 10.1007/BF00505086. [DOI] [PubMed] [Google Scholar]
  8. Hall D., Goedel-Meinen L., Rudolph W. Richtlinien zur medikamentösen Behandlung der arteriellen Hypertonie. Herz. 1978 Oct;3(5):289–299. [PubMed] [Google Scholar]
  9. Henning M. New trends in pharmacology. Acta Med Scand Suppl. 1977;606:87–93. doi: 10.1111/j.0954-6820.1977.tb18035.x. [DOI] [PubMed] [Google Scholar]
  10. Hökfelt B., Hedeland H., Dymling J. F. Studies on catecholamines, renin and aldosterone following Catapresan (2-(2,6-dichlor-phenylamine)-2-imidazoline hydrochloride) in hypertensive patients. Eur J Pharmacol. 1970;10(3):389–397. doi: 10.1016/0014-2999(70)90212-8. [DOI] [PubMed] [Google Scholar]
  11. Hökfelt B., Hedeland H., Hansson B. G. The effect of clonidine and penbutolol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. Arch Int Pharmacodyn Ther. 1975 Feb;213(2):307–321. [PubMed] [Google Scholar]
  12. Jain A. K., Ryan J. R., Vargas R., McMahon F. G. Efficacy and acceptability of different dosage schedules of clonidine. Clin Pharmacol Ther. 1977 Apr;21(4):382–387. doi: 10.1002/cpt1977214382. [DOI] [PubMed] [Google Scholar]
  13. Kirch W., Distler A. Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):132–135. [PubMed] [Google Scholar]
  14. Kleinlogel H., Scholtysik G., Sayers A. C. Effects of clonidine and BS 100-141 on the EEG sleep pattern in rats. Eur J Pharmacol. 1975 Aug;33(1):159–163. doi: 10.1016/0014-2999(75)90151-x. [DOI] [PubMed] [Google Scholar]
  15. Laverty R. The mechanisms of action of some antihypertensive drugs. Br Med Bull. 1973 May;29(2):152–157. doi: 10.1093/oxfordjournals.bmb.a070986. [DOI] [PubMed] [Google Scholar]
  16. Lidbrink P. The effect of lesions of ascending noradrenaline pathways on sleep and waking in the rat. Brain Res. 1974 Jul 5;74(1):19–40. doi: 10.1016/0006-8993(74)90109-7. [DOI] [PubMed] [Google Scholar]
  17. Loew D. M., Waite R. Proceedings: A quantitative assessment of the effects of clonidine on pre-ganglionic sympathetic nerve activity in the cat. Br J Pharmacol. 1974 Mar;50(3):456P–457P. [PMC free article] [PubMed] [Google Scholar]
  18. McMahon F. G., Ryan J. R., Jain A. K., Vargas R., Vanov S. K. Guanabenz in essential hypertension. Clin Pharmacol Ther. 1977 Mar;21(3):272–277. doi: 10.1002/cpt1977213272. [DOI] [PubMed] [Google Scholar]
  19. Metz S. A., Halter J. B., Porte D., Jr, Robertson R. P. Suppression of plasma catecholamines and flushing by clonidine in man. J Clin Endocrinol Metab. 1978 Jan;46(1):83–90. doi: 10.1210/jcem-46-1-83. [DOI] [PubMed] [Google Scholar]
  20. Page L. B., Yager H. M., Sidd J. J. Drugs in the management of hypertension. Part II. Am Heart J. 1976 Jul;92(1):114–118. doi: 10.1016/s0002-8703(76)80410-3. [DOI] [PubMed] [Google Scholar]
  21. Putzeys M. R., Hoobler S. W. Comparison of clonidine and methyldopa on blood pressure and side effects in hypertensive patients. Am Heart J. 1972 Apr;83(4):464–468. doi: 10.1016/0002-8703(72)90036-1. [DOI] [PubMed] [Google Scholar]
  22. Reid J. L., Tangri K. K., Wing L. M. The central hypotensive action of clonidine and propranolol in animals and man. Prog Brain Res. 1977;47:369–383. doi: 10.1016/S0079-6123(08)62740-5. [DOI] [PubMed] [Google Scholar]
  23. Reid J. L., Wing L. M., Mathias C. J., Frankel H. L., Neill E. The central hypotensive effect of clonidine. Studies in tetraplegic subjects. Clin Pharmacol Ther. 1977 Apr;21(4):375–381. doi: 10.1002/cpt1977214375. [DOI] [PubMed] [Google Scholar]
  24. Renzini V., Brunori C. A., Valori C. A sensitive and specific fluorimetric method for the determination of noradrenalin and adrenalin in human plasma. Clin Chim Acta. 1970 Dec;30(3):587–594. doi: 10.1016/0009-8981(70)90249-4. [DOI] [PubMed] [Google Scholar]
  25. Saameli K., Scholtysik G., Waite R. Pharmacology of BS 100-141, a centrally acting antihypertensive drug. Clin Exp Pharmacol Physiol. 1975;Suppl 2:207–212. [PubMed] [Google Scholar]
  26. Sattler R. W., van Zwieten P. A. Acute hypotensive action of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155) after infusion into the cat's vertebral artery. Eur J Pharmacol. 1967 Oct;2(1):9–13. doi: 10.1016/0014-2999(67)90016-7. [DOI] [PubMed] [Google Scholar]
  27. Schmitt H., Fénard S. Action of -adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneimittelforschung. 1973 Jan;23(1):40–45. [PubMed] [Google Scholar]
  28. Scholtysik G., Lauener H., Eichenberger E., Bürki H., Salzmann R., Müller-Schweinitzer E., Waite R. Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141). Arzneimittelforschung. 1975 Oct;25(10):1483–1491. [PubMed] [Google Scholar]
  29. Seus R., Seus H. Die Wirkung von Bellergal auf die Fahrtauglichkeit. Med Klin. 1972 Jun 30;67(26):923–927. [PubMed] [Google Scholar]
  30. Starke K., Borowski E., Taube H. D., Endo T. Mechanism of action of antihypertensive agents. Contrib Nephrol. 1977;8:151–161. doi: 10.1159/000400625. [DOI] [PubMed] [Google Scholar]
  31. Walker B. R., Shah R. S., Ramanathan K. B., Vanov S. K., Helfant R. H. Guanabenz and methyldopa on hypertension and cardiac performance. Clin Pharmacol Ther. 1977 Dec;22(6):868–874. doi: 10.1002/cpt1977226868. [DOI] [PubMed] [Google Scholar]
  32. Whitsett T. L., Chrysant S. G., Dillard B. L., Anton A. H. Abrupt cessation of clonidine administration: a prospective study. Am J Cardiol. 1978 Jun;41(7):1285–1290. doi: 10.1016/0002-9149(78)90887-1. [DOI] [PubMed] [Google Scholar]
  33. Wing L. M., Reid J. L., Davies D. S., Neill E. A., Tippett P., Dollery C. T. Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol. 1977 Dec 28;12(6):463–469. doi: 10.1007/BF00561067. [DOI] [PubMed] [Google Scholar]
  34. Zaimis E. Hypotensive drugs: Peripheral versus central effects. Contrib Nephrol. 1977;8:142–150. doi: 10.1159/000400624. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES